🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Financial Toxicity in #Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #FinancialToxicity #PallOnc #CostsOfCare #GeriOnc Fumiko Ladd Chino, MD, FASCO Jeffrey peppercorn MD Yousuf Zafar, MD MHS Jame Abraham, MD, FACP

🚨OncoAlert 🚨 #FinancialToxicity special issue JCO Oncology Practice is LIVE today! We hope these 📄 will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap!

A must read for all #oncology clinicians & researchers! Job well done by JCO Oncology Practice AE's Fumiko Ladd Chino, MD, FASCO Ryan Nipp, MD, MPH, FASCO under EIC Jeffrey peppercorn MD leadership for this important special series on #FinancialToxicity! @AS Jame Abraham, MD, FACP @manalipatelmd Gabrielle

How to efficiently screen for financial toxicity in practice? 🤔🤔🤔 See this important study as well as a great review of the development and impact of COST and review of all tools to address Fin Tox in research and practice in JCO Oncology Practice ! ascopubs.org/doi/10.1200/OP…

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer | New England Journal of Medicine ⁦OncoAlert⁩ ⁦NSABP Foundation⁩ ⁦NRG Oncology⁩ nejm.org/doi/full/10.10…

New study led by Jeffrey peppercorn MD informs policy debate on CPA foundations' role in the US health insurance safety net, examining Medicare's challenges in ensuring access to care for older patients with chronic illness. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Ryan Nipp, MD, MPH, FASCO OncoAlert

Dato-DXd is the third Topo1 ADC FDA-approved for treating breast cancer. Multiple ongoing phase 3 trials promise to expand its indication to earlier settings, including the curative setting. Here’s 10 facts to know on Dato-DXd (🧵):

🎙️Beyond excited to host a newly relaunched ASCO podcast with 1st episode: "Debt or Dying: The @JCOOP #FinancialToxicity Special Issue". My guests are Drs Ryan Nipp, MD, MPH, FASCO (my co-editor) and Dr. Kelly Shanahan (contributing author to the title piece on the lived experience of patients).

I sit down with co-editor & Dr. Ryan Nipp, MD, MPH, FASCO , & contributing author Dr. Dr. Kelly Shanahan to have a candid conversation about #financialtoxicity, the lived experience for patients, & what we can do to move the needle on affordability in cancer care. JCO Oncology Practice joppodcast.libsyn.com/debt-or-dying-…

Listen to the latest #JCO Cancer Stories: The Art of Oncology episode "Did I Mess Up Today?” Dr. John Sweetenham shares his reflections on his shrinking clinical comfort zone from his #JCOOP article. Lidia Schapira #ASCODailyNews #OncTwitter ➡️ brnw.ch/21wQaTm

#FinancialToxicity screening at scale is essential to ensure we identify (& HELP) people at risk for financial harm -before they are harmed. This 📄 of >38,000 pts shows that the validated COST tool can be simplified to 2️⃣ questions for easier integration into clinical workflows.

Validation of a Single Item Measure for Financial Toxicity Screening in Patients With Breast #Cancer. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #FinancialToxicity #BreastCancer #SuppOnc #CostsOfCare

Thank you ⁦Anant Madabhushi⁩ and his colleagues from ⁦Emory University⁩ for this must read - excellent review for clinicians on Artificial Intelligence ascopubs.org/doi/10.1200/OP… ⁦JCO Oncology Practice⁩ ⁦OncoAlert⁩ ⁦Jeffrey peppercorn MD⁩

Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring | JCO Oncology Practice #JCOOP OncoAlert ascopubs.org/doi/10.1200/OP…

Thematic take on ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually get the agent, the only real question is:

It continues to be a great honor to serve on the JCO Oncology Practice Editorial Board; very proud of the The McClelland Lab’s 2024 proton #RadOnc paper ➡️ most downloaded editorial in 2024! Always open for submission, 20 years strong! ascopubs.org/toc/op/current #ASCO25 #RepresentationMatters

Thank you and congratulations to ⁦Sagar Lonial MD⁩ and ⁦Apar Kishor Ganti⁩ - The amazing Associate Editors of ⁦JCO Oncology Practice⁩ now rotating off their responsibilities! It was a privilege to work with them for the past 6 years ! ⁦Jeffrey peppercorn MD⁩ !

Our oral presentation at #ASCO2025 today: environmental burden isn’t just a health hazard - it’s a cancer risk. Counties with higher pollution burden see more cancer, especially lung cancer. Calls for policy action to address environmental justice. UAB O'Neal Comprehensive Cancer Center Azar Abadi

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Another great #ASCO25 wonderful to see my amazing JCO Oncology Practice colleagues! 📝 Loved Dr. DeMichele’s discussion of SERENA-6 and the incredible CHALLENGE trial of exercise in colon cancer survivors. 🏃‍♂️ And a chance to hang out for a few hours with my daughter! 🥰